^
    Back
    Association details:
    Biomarker:LMO7-ALK rearrangement
    Cancer:Lung Adenocarcinoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Front Oncol
    Title:

    LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report

    Published date:
    05/19/2022
    Excerpt:
    ...we report a female patient with metastatic lung adenocarcinoma harboring LMO7-ALK (L15, A20) rearrangement revealed by NGS. The patient received crizotinib as first-line treatment and has achieved partial response with a progression-free survival over 1 year.
    DOI:
    https://doi.org/10.3389/fonc.2022.841493